Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost – Xconomy
Xconomy |
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR–T Boost
Xconomy The alliance continues Gilead's dealmaking spree in CAR–T, a method of cancer treatment in which a patient's immune cells are removed, modified, and re-infused into the body to find and kill cancer. Gilead's run began when it paid nearly $12 billion … Gilead and Sangamo deal shows that CRISPR still has competition Sangamo Inks $3B Deal with CAR T Leader Gilead How Gilead Sciences Is Betting Big on Gene Editing |
